P
CORT icon

Pitcairn’s Corcept Therapeutics CORT Stock Holding History

Pitcairn’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,161
Closed -$305K – 647
2025
Q2 		$305K Buy
4,161
+23
+0.6% +$1.67K 0.02% 559
2025
Q1 		$473K Hold
4,138
– – 0.03% 440
2024
Q4 		$209K Buy
+4,138
New +$217K 0.01% 672
2019
Q1 		– Sell
-12,761
Closed -$171K – 504
2018
Q4 		$171K Sell
12,761
-1,084
-8% -$14.3K 0.02% 426
2018
Q3 		$194K Sell
13,845
-703
-5% -$9.82K 0.02% 516
2018
Q2 		$228K Buy
14,548
+1,062
+8% +$18.5K 0.02% 495
2018
Q1 		$222K Buy
+13,486
New +$250K 0.02% 477

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Pitcairn's CORT Position: Q3 2025 in Review

Pitcairn sold out of Corcept Therapeutics (CORT) in Q3 2025, closing a stake of 4,161 shares — an estimated $305K sold.

Pitcairn first reported a position in CORT in Q1 2018 and held it in 7 quarters. The position peaked at $473K in Q1 2025. 429 funds tracked by Wall St. Rank hold CORT as of Q3 2025.

  • Pitcairn reported no remaining Corcept Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Pitcairn sold 4,161 Corcept Therapeutics shares in Q3 2025, an estimated $305K.
  • Pitcairn first reported a position in Corcept Therapeutics in Q1 2018 and held it in 7 quarters.
  • Pitcairn's Corcept Therapeutics position peaked at $473K in Q1 2025.
  • 429 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2025.

Based on Pitcairn's 13F filing for Q3 2025, filed 12 Nov 2025.